R03AG091099

Discovery of disease-associated eQTLs with a scalable human in vitro model of microglia-astrocyte interactions - Project summary

Dementias are projected to become the most burdening group of diseases, expected to affect over 150 million people worldwide by 2050, and Alzheimer’s disease (AD) is the most common among them.

Currently, over 6 million Americans are living with AD.

While there have been several recently-approved drugs for AD, these drugs target amyloid beta plaques – just one facet of the disease – and have not proven effective in all patients.

Non-neuronal cell types in the brain such as microglia (the brain’s immune cells) and astrocytes (star-shaped helper cells) play a critical role in disease progression but have been traditionally understudied.

Microglia are known to be activated by amyloid beta plaques and they were ascribed both a protective and a detrimental role.

They were shown to induce a toxic state in astrocytes.

The microglia’s behavior is likely influenced by patient genetics, which might explain why the majority of AD risk genes are expressed in microglia.

To determine which of the 90 known AD-associated genetic variants exert their effect through microglia, we need a better understanding of the functional links between a variant and the disease.

This requires large-scale studies of diseased, human cells from genetically diverse patients, as there is a wide variety of genetic variants that can influence AD risk.

This project proposes to develop an automatable protocol for the creation of human induced pluripotent stem cell (iPSC)-derived microglia (IMG) and their co-culture with primary astrocytes.

Standardized co-cultures of IMGs from AD patients and primary astrocytes will allow scientists to observe how these cells interact in a diseased environment, better understand known variants, and possibly identify new risk variants.

Attaining sufficient statistical power for the identification of novel variants requires many cell lines, which can only be achieved with robotic automation.

This study will serve as a proof of concept to demonstrate that such co-culture systems be automated and will later be scaled up to include additional cell lines.

It will furthermore help to understand how certain genetic variants contribute to AD, which might inspire new therapeutic approaches.

Jackson Laboratory

<P>TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE.&NBSP;</P>

93.866 - Aging Research

National Institute on Aging (NIA) [HHS - NIH]

New York, New York 100193545 United States

Single Zip Code

Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional) (PA-25-246)